1. Home
  2. FTF vs ALT Comparison

FTF vs ALT Comparison

Compare FTF & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FTF
  • ALT
  • Stock Information
  • Founded
  • FTF 2003
  • ALT 1997
  • Country
  • FTF United States
  • ALT United States
  • Employees
  • FTF N/A
  • ALT N/A
  • Industry
  • FTF Finance/Investors Services
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • FTF Finance
  • ALT Health Care
  • Exchange
  • FTF Nasdaq
  • ALT Nasdaq
  • Market Cap
  • FTF 259.6M
  • ALT 292.0M
  • IPO Year
  • FTF N/A
  • ALT N/A
  • Fundamental
  • Price
  • FTF $6.44
  • ALT $3.68
  • Analyst Decision
  • FTF
  • ALT Strong Buy
  • Analyst Count
  • FTF 0
  • ALT 6
  • Target Price
  • FTF N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • FTF 153.9K
  • ALT 2.9M
  • Earning Date
  • FTF 01-01-0001
  • ALT 08-12-2025
  • Dividend Yield
  • FTF 11.45%
  • ALT N/A
  • EPS Growth
  • FTF N/A
  • ALT N/A
  • EPS
  • FTF N/A
  • ALT N/A
  • Revenue
  • FTF N/A
  • ALT $20,000.00
  • Revenue This Year
  • FTF N/A
  • ALT N/A
  • Revenue Next Year
  • FTF N/A
  • ALT $346,228.97
  • P/E Ratio
  • FTF N/A
  • ALT N/A
  • Revenue Growth
  • FTF N/A
  • ALT N/A
  • 52 Week Low
  • FTF $5.76
  • ALT $2.90
  • 52 Week High
  • FTF $6.56
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • FTF 54.79
  • ALT 41.68
  • Support Level
  • FTF $6.37
  • ALT $3.34
  • Resistance Level
  • FTF $6.41
  • ALT $3.91
  • Average True Range (ATR)
  • FTF 0.03
  • ALT 0.20
  • MACD
  • FTF 0.01
  • ALT 0.06
  • Stochastic Oscillator
  • FTF 88.89
  • ALT 42.86

About FTF Franklin Limited Duration Income Trust of Beneficial Interest

Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: